genomic-variant-interpretation

To classify genomic variants using the ACMG framework, apply a structured reasoning process that evaluates pathogenicity, clinical actionability, and gene-disease validity using population frequency filtering and evidence-based criteria weighting.

Interpreting conflicting pathogenicity evidence requires reconciling population frequency data from gnomAD with clinical database entries like ClinVar using established decision trees and weighted evidence criteria to ensure scientific accuracy.

Applying AMP/ASCO/CAP standards for somatic variant interpretation involves evaluating clinical actionability and pathogenicity through a structured, evidence-based reasoning framework aligned with 2017 professional guidelines.

Yes, in silico predictors like REVEL and SpliceAI can be used for clinical variant classification by integrating their functional predictions into the evidence-based criteria weighting process to support pathogenicity decisions.

The PVS1 decision tree is needed when evaluating novel loss-of-function variants for pathogenicity, guiding the agent to systematically check gene-disease validity and weigh functional evidence against population frequency data.

Yes, this variant interpretation approach supports both germline and somatic workflows by applying the 2015 ACMG/AMP and 2017 AMP/ASCO/CAP classification frameworks respectively to ensure clinical research and diagnostic accuracy.